---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002093"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:00:26.727484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports FY2024 net loss $64.8M, cash $76.8M; PBFT02 shows durable PGRN elevation in FTD-GRN

## Summary
- Cash, cash equivalents and marketable securities $76.8M as of Dec 31, 2024, down from $114.3M; runway extended into 1Q 2027.
- Net loss of $12.7M ($0.20 per share) for Q4 2024 vs $16.8M ($0.30) a year ago; full year net loss $64.8M ($1.07) vs $102.1M.
- Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to 13-27 ng/mL at 6 months (n=4) and 22-34 ng/mL at 12 months (n=2).
- Plasma NfL levels 13% lower vs baseline at 12 months vs expected 29% annual increase from natural history data.
- First FTD-GRN patient enrolled with Dose 2 (50% lower); plan to report 12-month data and interim Dose 2 data in 2H 2025.

## SEC filing metadata
- accession: 0001558370-25-002093
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837025002093/0001558370-25-002093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837025002093/pasg-20250304x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002093
- JSON: https://secwatch.observer/filing/0001558370-25-002093.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.